Novruzov, E.
Dendl, K.
Ndlovu, H.
Choyke, P. L.
Dabir, M.
Beu, M.
Novruzov, F.
Mehdi, E.
Guliyev, F.
Koerber, S. A.
Lawal, I.
Niegisch, G.
Debus, J.
Haberkorn, U.
Sathekge, M.
Giesel, F. L.
Funding for this research was provided by:
Heinrich-Heine-Universität Düsseldorf
Article History
Received: 10 November 2021
Revised: 15 February 2022
Accepted: 28 February 2022
First Online: 29 March 2022
Declarations
:
: All procedures performed in studies involving human participants were approved by ethics committee and carried out in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
: UH and FLG have a patent application for quinolone based FAP-targeting agents for imaging and therapy in nuclear medicine. UH and FLG also have shares of a consultancy group for iTheranostics. FLG is also advisor at ABX, Telix, and SOFIE Biosciences. SAK reports grants from Viewray Inc. and honoraria from IBA Dosimetry, outside the submitted work. The other authors declare no conflict of interest regarding this manuscript.